Targeted Drug Delivery Partnering 2009-2014
Published: Aug 2014 | Publisher: Current Partnering | Pages: 150SUMMARY
Targeted Drug Delivery Partnering 2009-2014 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.
TABLE OF CONTENTS
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in targeted drug delivery partnering
2.1. Introduction
2.2. Targeted drug delivery partnering over the years
2.3. Big pharma Targeted drug delivery dealmaking activity
2.4. Big biotech Targeted drug delivery dealmaking activity
2.5. Targeted drug delivery partnering by deal type
2.6. Targeted drug delivery partnering industry sector
2.7. Targeted drug delivery partnering by stage of development
2.8. Targeted drug delivery partnering by therapy type
2.9. Disclosed financial deal terms for targeted drug delivery partnering
2.9.1 Targeted drug delivery headline values
2.9.2 Targeted drug delivery upfront payments
2.9.3 Targeted drug delivery milestone payments
2.9.4 Targeted drug delivery royalty rates
Chapter 3 – Leading Targeted drug delivery deals
3.1. Introduction
3.2. Top Targeted drug delivery deals by value
Chapter 4 – Targeted drug delivery dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By therapy type
Hospital care
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynecology
Hematology
Hospital care
Immunology
Infectious diseases
Metabolic & endocrinology
Musculoskeletal
Obstetrics
Orphan Diseases
Oncology
Ophthalmology
Pediatrics
Psychiatry
Public health
Rehabilitation medicine
Respiratory
Sensory organ
Sexual health
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Table of figures
Figure 1: Targeted drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – Targeted drug delivery deals 2009 to 2014
Figure 3: Big biotech– top 50 – Targeted drug delivery deals 2009 to 2014
Figure 4: Big pharma Targeted drug delivery deal frequency – 2009 to 2014
Figure 5: Big biotech Targeted drug delivery deal frequency – 2009 to 2014
Figure 6: Targeted drug delivery partnering by deal type since 2009
Figure 7: Targeted partnering by industry sector since 2009
Figure 8: Targeted drug delivery partnering by stage of development since 2009
Figure 9: Targeted drug delivery partnering by therapy type since 2009
Figure 10: Targeted drug delivery deals with a headline value
Figure 11: Targeted drug delivery deals with upfront payment values
Figure 12: Targeted deals with milestone payments
Figure 13: Targeted drug delivery deals with royalty rates, %
Figure 14: Top Targeted drug delivery deals by value since 2009
Figure 15: Online partnering resources
Figure 16: Forthcoming partnering events
Figure 17: Deal type definitions
Chapter 1 – Introduction
Chapter 2 – Trends in targeted drug delivery partnering
2.1. Introduction
2.2. Targeted drug delivery partnering over the years
2.3. Big pharma Targeted drug delivery dealmaking activity
2.4. Big biotech Targeted drug delivery dealmaking activity
2.5. Targeted drug delivery partnering by deal type
2.6. Targeted drug delivery partnering industry sector
2.7. Targeted drug delivery partnering by stage of development
2.8. Targeted drug delivery partnering by therapy type
2.9. Disclosed financial deal terms for targeted drug delivery partnering
2.9.1 Targeted drug delivery headline values
2.9.2 Targeted drug delivery upfront payments
2.9.3 Targeted drug delivery milestone payments
2.9.4 Targeted drug delivery royalty rates
Chapter 3 – Leading Targeted drug delivery deals
3.1. Introduction
3.2. Top Targeted drug delivery deals by value
Chapter 4 – Targeted drug delivery dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By therapy type
Hospital care
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynecology
Hematology
Hospital care
Immunology
Infectious diseases
Metabolic & endocrinology
Musculoskeletal
Obstetrics
Orphan Diseases
Oncology
Ophthalmology
Pediatrics
Psychiatry
Public health
Rehabilitation medicine
Respiratory
Sensory organ
Sexual health
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Table of figures
Figure 1: Targeted drug delivery partnering since 2009
Figure 2: Big pharma – top 50 – Targeted drug delivery deals 2009 to 2014
Figure 3: Big biotech– top 50 – Targeted drug delivery deals 2009 to 2014
Figure 4: Big pharma Targeted drug delivery deal frequency – 2009 to 2014
Figure 5: Big biotech Targeted drug delivery deal frequency – 2009 to 2014
Figure 6: Targeted drug delivery partnering by deal type since 2009
Figure 7: Targeted partnering by industry sector since 2009
Figure 8: Targeted drug delivery partnering by stage of development since 2009
Figure 9: Targeted drug delivery partnering by therapy type since 2009
Figure 10: Targeted drug delivery deals with a headline value
Figure 11: Targeted drug delivery deals with upfront payment values
Figure 12: Targeted deals with milestone payments
Figure 13: Targeted drug delivery deals with royalty rates, %
Figure 14: Top Targeted drug delivery deals by value since 2009
Figure 15: Online partnering resources
Figure 16: Forthcoming partnering events
Figure 17: Deal type definitions
$995
My Basket
 | Actelion Partnering 2009-2014 | $995 |
| TOTAL | $995 | |
| Empty Cart | ||
| ||
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed